Navigation Links
WorldHeart Announces Effectiveness of Reverse Stock Split
Date:10/29/2008

OAKLAND, Calif., Oct. 29 /PRNewswire-FirstCall/ -- (Nasdaq: WHRTD) -- World Heart Corporation (WorldHeart or the Company), effected a reverse stock split of 30-to-1 after filing of articles of amendment with Industry Canada under the Canada Business Corporations Act and commenced trading on the NASDAQ Capital Market on a post-consolidation basis on October 28, 2008. The Corporation's shareholders approved the proposal for a reverse stock split at a Special Meeting of Shareholders held on October 9, 2008 and the Board of Directors determined to implement the reverse stock split at a 30-to-1 ratio. Completion of the reverse split is intended to allow WorldHeart to keep its listing on the NASDAQ Capital Market, subject to continued compliance with all of the other listing requirements.

The Company's common shares began trading on the NASDAQ Capital Market on a post-consolidation basis (every thirty common shares of WorldHeart combined into one common share) as of the opening of trading on October 28, 2008 under the symbol "WHRTD" and under a new CUSIP number 980905400. The symbol "WHRTD" will remain in effect until November 25, 2008 and subsequently will resume trading under the symbol "WHRT". The reverse stock split will not affect the ownership of option and warrant holders. Upon the exercise of any options or warrants, resulting shares issued will be issued on a post-consolidation basis. No scrip or fractional certificates will be issued in connection with the reverse stock split. Shareholders who otherwise would be entitled to receive fractional shares because they hold a number of common shares not evenly divisible by thirty will not be entitled to cash compensation and such holders will lose any entitlement to such fractional s
'/>"/>

SOURCE World Heart Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WorldHeart Receives Favorable Decision to Continue NASDAQ Listing
2. WorldHeart Receives Non-Compliance Letter From NASDAQ Stock Market
3. WorldHeart Announces Voluntary Delisting from the Toronto Stock Exchange
4. WorldHeart Announces Possible Delisting Action by NASDAQ
5. WorldHeart Notified of TSX Delisting Review
6. WorldHeart Appoints David Pellone Chief Financial Officer
7. XELR8 Holdings Announces Conference Call to Review Third Quarter Financial Results
8. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
9. Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital
10. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
11. Berger & Montague Announces Class Action Lawsuit Against Elan Corporation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...rsity researchers, from the School of Medicine,s D...ic pathways by which products of lipid peroxidatio..., are metabolized. The pathways were identified by... analysis. The findings shed new light on the mech...butyrate, also known as "the date rape drug." The ...
(Date:12/4/2009)...ure done immediately or 3 weeks later, study shows...Timing of surgical repair or reconstruction of mul...t outcome, a new study has found. , Multiple-li...slocations that can occur in high-impact car crash...rm surgery to repair these injuries hasn,t been de...
(Date:12/4/2009)...r Applauds Historic Effort but Points out Potentia...n Final Health Care Reform ,, NEW YORK, Dec. ...rnal of Medicine today published a Perspective o...hored by Irwin Redlener, M.D., president, Children...isaster Preparedness and Professor of Clinical Pop...
(Date:12/4/2009)...through hookah, research shows , , FRIDA...afer than cigarettes for smoking tobacco, research...oke tobacco with a water pipe inhale carbon monoxi... disease and nicotine addiction. , The study in...bacco using a water pipe and a single cigarette. A...
(Date:12/4/2009)... Dec. 4 When the spread ...epartment of Health Services needed to get more in...fore. Join Sonic Foundry, Inc. (Nasdaq: SOFO ),...sting and knowledge management, for a live webinar... of Health Services, will share how in-house webca...
Breaking Medicine News(10 mins):Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Water Pipes No Safer Than Cigarettes 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
...s Corp. (Nasdaq:,HMSY) today announced that it wil...onference, which will be held January 7-10, 2008 a...: http://www.newscom.com/cgi-bin/prnh/20030304/NY...ast of the Company,s presentation can be accessed ...
...nix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announc...porate overview, including an update of the compan..., at the upcoming JP Morgan 26th,Annual Healthcare...entation can be accessed,under "Calendar of Events...
...am for Lead Product, MENLO PARK, Calif., Dec. 20 ...t it has completed a private placement financing,r...opment of the company,s,novel antiplatelet therapy...on,from Prospect Venture Partners, Ridgeback Capit...
...-Opportunities program of Agriculture and ..., ON, Dec. 20 /PRNewswire-FirstCall/ - Bioniche Li...hnology-driven Canadian,biopharmaceutical company,... Ontario. The $5 million repayable,contribution ha...
..., 2007 Wiley-Blackwell, the scientific, technical...n Wiley & Sons, Inc (NYSE: JWa), (NYSE: JWb), and ...anisation dedicated to improving healthcare decisi...World Banks list of low-income economies (countrie...
...dds, study found , THURSDAY, Dec. 20 (HealthDay Ne...cy can boost a child,s risk of developing allergie...nska Institute, Stockholm, analyzed questionnaires...s, 2 years and 4 years. In addition, the researche...
Other Medicine News:Health News:Cogentus Pharmaceuticals Completes $62.5 Million Private Financing 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 2Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 3Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 4Health News:Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario 5Health News:Low-income countries now have free, one-click access to Cochrane Library 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2
(Date:12/4/2009)..., ANNAPOLIS, Md., Dec. 4 /PRNewswire-FirstCall/ -...se company developing medical countermeasures agai...ay the presentation of new data from the Company,s...zed recombinant Protective Antigen (rPA) based ant...er 16 months at various temperatures up to and inc...
(Date:12/4/2009)..., SAN DIEGO, Calif., Dec. 4 Sunev...ce company, today announced the appointment of Phi...fficer. In this role, Mr. Ranker will lead all Su...s including finance, accounting, IT, IR, administr...the Company,s senior management team. ,, "One ...
(Date:12/4/2009)..., BETHESDA, Md., Dec. 4 Drs. Neal ...prostate-specific antigen (PSA) recurrence from th...iochemical recurrence rate in a Phase III pivotal ...ection) or monthly leuprolide in prostate cancer p...ate cancer patients who received FIRMAGON 240/80 m...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 2Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 3Suneva Medical Announces Corporate Developments Including Appointment of Philip Ranker as Chief Financial Officer 4Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Middle Age Heart Risk Factors Shorten Mens Lives 57598 1Middle Age Heart Risk Factors Shorten Mens Lives 57598 2Middle Age Heart Risk Factors Shorten Mens Lives 57598 3Northwest Hospital 26 Medical Center to Join UW Medicine 57596 1Northwest Hospital 26 Medical Center to Join UW Medicine 57596 2Northwest Hospital 26 Medical Center to Join UW Medicine 57596 3U S Chamber 3A Medical Liability Reform Must Have Teeth to be Effective 57594 1
...r and Imaging Study) Results Demonstrate ...SAN DIEGO, Calif., Sept. 2 Volcano,Corporation (N...nufacturer of,intravascular ultrasound (IVUS) and ...oday the use of its VH(R) IVUS (Virtual Histology ...d Biomarker and Imaging Study). In,the study, Volc...
...sty and Stenting Safe and Effective in Patients ...t Surgery, WASHINGTON, Sept. 1 Data announced to...atients with very complex coronary,artery disease ...nd,drug-eluting stents rather than open-heart surg...hy and Interventions (SCAI). The one-year results,...
Other Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 2SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease 3
Endoscope
Neuroview 1.2 mm Neuroendoscopes
...atch is a synthetic absorbable implant for the bri...s. Ethisorb Dura Patch is pliable, regardless of b...e, care must be taken, while implanting, to ensure...de is oriented towards the cortex or the spinal co...
IDS-300 Electrosurgical Generator
Medicine Products: